Influence of doxycycline on clinical and angiographic outcome following percutaneous coronary intervention

Journal of Interventional Cardiology

Volumn 17, Issue 6, 2004, Pages 447-453

  Kannengiesser, Matthias ^a   Kaltenbach, Martin ^a   Stille, Wolfgang ^b   Reifart, Nicolaus ^c   Haase, Jürgen ^a,d  

^a Red Cross Hospital Cardiology Center   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c Main Taunus Heart Institute   (Germany)

^d Kardiologisches Centrum   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE;

ADULT; ADVERSE CLINICAL EVENT; AGED; ANGIOCARDIOGRAPHY; ANTIBIOTIC THERAPY; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DRUG EFFECT; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OBSERVATION; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RESTENOSIS; SMOKING; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; CHLAMYDOPHILA INFECTIONS; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY RESTENOSIS; DOXYCYCLINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL;

EID: 9244236003     PISSN: 08964327     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2004.04088.x     Document Type: Article

References (31)

1. Ross R. Atherosclerosis - An inflammatory disease. N Engl J Med 1999;340:115-126.
2. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: Is there a link? Lancet 1997;350:430-436.
3. Saikku P, Leinonen M, Mattila K, et al. Serological evidence of an association of a novel chlamydia TWAR with chronic coronary heart disease and acute myocardial infarction. Lancet 1988;2:983-986.
4. Ridker PM. Inflammation, infection, and cardiovascular risk: How good is the clinical evidence? Circulation 1998;97:1671-1674.
5. Camm AJ, Fox KM. Chlamydia pneumoniae (and other infective agents) in atherosclerosis and acute coronary syndromes: How good is the evidence? Eur Heart J 2000;21:1046-1051.
6. Stille W, Dittmann R, Just-Nübling GJ. Atherosclerosis due to chronic arteritis caused by Chlamydia pneumoniae: A tentative hypothesis. Infection 1997;25:281-285.
7. Ramirez JA. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia Pneumoniae/ Atherosclerosis Study Group. Ann Intern Med 1996;125:979-982.
8. Maass M, Bartels C, Engel PM, et al. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol 1998;31:827-832.
9. Fong IW, Chiu B, Viira E, et al. Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol 1997;35:48-52.
10. Laitinen K, Laurila A, Pyhala L, et al. Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect Immunol 1997;65:4832-4835.
11. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and the treatment with azithromycin prevents it in a rabbit model. Circulation 1998;97:633-636.
12. Gupta S, Leatham EW, Carrington D, et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997;96:404-407.
13. Gurfinkel E, Bozovich G, Daroca A, et al. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. ROXIS Study Group. Lancet 1997;350:404-407.
14. Gimenez-Sanchez F, Butler JC, Jernigan DB, et al. Treating cardiovascular disease with antimicrobial agents: A survey of knowledge, attitudes and practices among physicians in the United States. Clin Infect Dis 2001;33:171-176.
15. Kol A, Sukhova GK, Lichtman AH, et al. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation 1998;98:300-307.
16. Mayr M, Metzler B, Kiechl S, et al. Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins in Escherichia coli and Chlamydia pneumoniae: Immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. Circulation 1999;99:1560-1566.
17. Dechend R, Maass M, Gieffers J, et al. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-KB and induces tissue factor and PAI-1 expression: A potential link to accelerated arteriosclerosis. Circulation 1999;100:1369-1373.
18. Krull M, Klucken AC, Wuppermann FN, et al. Signal transduction pathways activated in endothelial cells following infection with Chlamydia pneumoniae. J Immunol 1999;162:4834-4841.
19. Kaukoranta-Tolvanen SS, Teppo AM, Laitinen K, et al. Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. Microb Pathog 1996;21:215-221.
20. Rodel J, Assefa S, Prochnau D, et al. Interferon-beta induction by Chlamydia pneumoniae in human smooth muscle cells. FEMS Immunol Med Microbiol 2001;32:9-I5.
21. Netea MG, Kullberg BJ, Galama JM, et al. Non-LPS components of Chlamydia pneumoniae stimulate cytokine production through Toll-like receptor 2-dependent pathways. Eur J Immunol 2002;32:1188-1195.
22. Wahl C, Oswald F, Simnacher U, et al. Survival of Chlamydia pneumoniae-infected Mono Mac 6 cells is dependent on NF-kappaB binding activity. Infect Immun 2001;69:7039-7045.
23. Neumann F, Kastrati A, Miethke T, et al. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): A randomised double-blind, placebo-controlled trial. Lancet 2001;357:2085-2089.
24. Gurfinkel E, Bozovich G, Beck E, et al. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J 1999;20:121-127.
25. Anderson JL, Muhlestein JB, Carlquist J, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 1999;99:1540-1547.
26. Yutani C, Imakita M, Ishibashi-Ueda H, et al. Coronary atherosclerosis and interventions: Pathological sequences and restenosis. Pathol Int 1999;49:273-290.
27. Miettinen H, Lehto S, Saikku P, et al. Association of Chlamydia pneumoniae and acute coronary heart disease events in non-insulin dependent diabetic and non-diabetic subjects in Finland. Eur Heart J 1996;17:682-688.
28. Thom DH, Grayston JT, Siscovick DS, et al. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA 1992;268:68-72.
29. Hahn DL, Golubjatnikov R. Smoking is a potential confounder of the Chlamydia pneumoniae-coronary artery disease association. Arterioscler Thromb 1992;12:945-947.
30. Karvonen M, Tuomilehto J, Pitkaniemi J, et al. Importance of smoking for Chlamydia pneumoniae seropositivity. Int J Epidemiol 1994;23:1315-1321.
31. Bauer-Krylov E, Madeo M, Stille W. Die Infektionshypothese als Erklärung der Androtropie des Herzinfarktes. Dtsch Med Wschr 2000;125:1095-1097.